The global Biobanking Market, valued at US$7.16 billion in 2024, stood at US$7.65 billion in 2025 and is projected to advance at a resilient CAGR of 9.1% from 2025 to 2030, culminating in a forecasted valuation of US$11.82 billion by the end of the period. Several factors contribute to the growth of the biobanking market, including growing focus on precision or personalized medicine, continuously expanding cell & gene therapy pipeline, and end-to-end automation for sample handling & storage. Additionally, the focus on sustainability and green-lab solutions offers growth opportunities for market players. However, long-term funding stability for public biobanks is a challenge faced by the market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=594
Browse in-depth TOC on ‘Biobanking Market’
350 – Tables
45 – Figures
300 – Pages
By product, the biobanking market is segmented into equipment and consumables. The equipment market is further split into freezers & refrigerators, temperature & humidity control systems, cryogenic storage systems, thawing equipment, alarm & monitoring systems, and other equipment. Freezers & refrigerators held the largest share of the biobanking equipment market in 2024 as they are essential to the core operations of any biobank, ensuring the long-term storage and preservation of biological samples such as blood, tissues, and DNA. Given the nature of biobank samples, maintaining optimal temperature conditions is critical to preserving sample integrity for future research, diagnostics, and therapeutic development. Cryogenic freezers, in particular, are indispensable for the preservation of cell lines, stem cells, and genetic materials, often requiring ultra-low temperatures to maintain viability for years.
By end users, the biobanking services market is segmented into pharmaceutical & biotechnology companies & CROs, and academic & research institutes. The pharmaceutical & biotechnology companies & CROs segment is estimated to register the highest growth rate during the forecast period, driven by the rising demand for biologics, biosimilars, and advanced therapies such as cell and gene therapies. These companies are expanding their therapeutic offerings, which are dependent on cell lines, and clinical sample management is highly demanded by these end users.
By geography, the biobanking market is segmented into six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to register the highest growth rate during the forecast period, since countries like China, India, and Japan ramp up their research capabilities, biobanks in the region are gaining momentum, becoming critical to advancing drug discovery, clinical trials, and population-based health studies. The growing prevalence of chronic diseases, coupled with the region’s aging population, has spurred a need for comprehensive biobanking solutions to support healthcare innovations and research into disease prevention and treatment.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=594
The key players in the biobanking market include Thermo Fisher Scientific Inc. (US), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (BD) (US), Qiagen (Germany), Merck KGaA (Germany), Labcorp (US), Eurofins Scientific (Luxembourg), and Cryoport (US), among other players.
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/biobanking-devices-market-594.html